URL of this page: https://medlineplus.gov/news/fullstory_165902.html

Compound in Pot Eases Severe Form of Epilepsy

Cannabidiol not associated with the 'high' of marijuana, researchers report
(*this news item will not be available after 08/22/2017) Wednesday, May 24, 2017

WEDNESDAY, May 24, 2017 (HealthDay News) -- A landmark clinical trial has shown that a compound in marijuana can ease life-threatening seizures in children with a rare and devastating form of epilepsy.

Cannabidiol -- a non-intoxicating chemical -- reduced seizure frequency by 39 percent in patients with Dravet Syndrome, researchers report.

This is the first randomized, controlled trial to show that cannabidiol (CBD) can help control seizures in some people with epilepsy, said study author Dr. Orrin Devinsky. He is director of the Comprehensive Epilepsy Center at NYU Langone Medical Center in New York City.

"It's a big landmark in the scientific study of cannabis, and it's a major landmark in epilepsy care," Devinsky said. "After four millennia of using cannabis to treat epilepsy, we now have for the first time scientifically rigorously obtained data that this specific compound works in this specific form of epilepsy."

Brandy Fureman, vice president of research and new therapies for the Epilepsy Foundation, agreed that the new trial provides "gold standard" evidence of cannabidiol's effectiveness.

"We now have strong evidence that CBD [cannabidiol] can be helpful for some people with Dravet Syndrome," Fureman said. "This trial provides important information for doctors and families who are trying to decide if CBD should be tried in their child's particular case, how it can be administered safely, and what side effects to watch out for."

The clinical trial relied on a liquid formulation of cannabidiol called Epidiolex, which was developed by British company GW Pharmaceuticals.

Epidiolex has not been approved by the U.S. Food and Drug Administration. GW Pharmaceuticals -- which paid for the clinical trial -- expects to file for FDA approval of the drug this year.

In the trial, Devinsky and his colleagues recruited 120 children and teenagers with Dravet Syndrome, which generally starts causing severe seizures within the first year of life. The seizures often are prolonged and repetitive; 1 in 5 children with Dravet Syndrome do not live to see age 20, Devinsky said.

The patients, ranging in age from 2 to 18, were randomly assigned to receive every day either 20 milligrams of liquid Epidiolex or a placebo, on top of their usual medication. The study took place across 23 sites in the United States and Europe, and lasted 14 weeks.

Children receiving Epidiolex experienced fewer seizures, going from an average of 12 convulsive seizures a month before the study to about six seizures a month. Three patients' seizures stopped entirely.

At the same time, children in the placebo group only had a slight reduction in seizures, from about 15 to 14 seizures a month.

More than 9 out of 10 children did experience side effects from treatment with Epidiolex, the researchers found. The most common side effects were vomiting, fatigue and fever.

Although these symptoms generally were mild to moderate, eight children in the Epidiolex group withdrew from the trial due to side effects, compared to one patient in the placebo group.

The study appears in the May 25 issue of the New England Journal of Medicine.

Despite the side effects, Epidiolex seems as safe as other epilepsy medications, said Dr. Samuel Berkovic, director of the University of Melbourne's Epilepsy Research Center in Australia.

"Side effects are always an issue, but the drug was tolerated about as well as conventional anti-epileptic drugs," said Berkovic, who wrote an editorial accompanying the clinical trial report.

"Like other epilepsy medications, CBD appears to work for some people and not for others," Fureman said. "Like other epilepsy treatments, there are side effects of CBD that should be considered."

Cannabidiol-based treatments are available in the 29 states that have approved medical marijuana, Devinsky said.

The problem is that these products aren't manufactured under strict FDA oversight, and might contain varying levels of cannabidiol. The products also might contain THC, the biochemical in marijuana that produces a high, Devinsky said.

"Hopefully, in the next year to two years Epidiolex would get FDA approval, and then this drug could be available in pharmacies and people could have it covered by their health insurance," Devinsky said.

"In the interim, people are getting something like this from medical dispensaries in states with legalized medical marijuana," he continued. "The question is, how different are batches to batches."

SOURCES: Orrin Devinsky, M.D., director, Comprehensive Epilepsy Center, NYU Langone Medical Center, New York City; Brandy Fureman, Ph.D., vice president, research and new therapies, Epilepsy Foundation; Samuel Berkovic, M.D., director, University of Melbourne's Epilepsy Research Center, Australia; May 25, 2017, New England Journal of Medicine

HealthDay
News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.
More Health News on
Epilepsy
Marijuana
Recent Health News

Related MedlinePlus Health Topics